Managing Chorea in Huntington’s Disease: Symptoms and Treatments

How to Manage Chorea in Huntington’s Disease

How to Manage Chorea in Huntington’s Disease
Adobe Stock; Everyday Health

More than 90 percent of people with the genetic condition Huntington’s disease develop chorea — involuntary movements that can interfere with daily activities, communication, and independence.

While chorea can be disruptive, it doesn’t always need to be treated right away. When symptoms do begin to affect daily life, medications and supportive strategies can help reduce movements and allow people with Huntington’s disease to remain independent.

What Is Chorea?

Chorea is a movement disorder that causes brief, irregular, involuntary movements that may affect the face, trunk, arms, and legs. These movements can look like fidgeting or restlessness and may vary from subtle to more pronounced over time.

These symptoms can interfere with smaller and larger movements, including walking and balance. Speech and swallowing can be problematic as well, in part because the tongue may move in and out of the mouth or move in different directions, known as jack-in-the-box tongue.

These “extra wiggly movements” come from overactivity of the hormone dopamine, in the part of the brain that regulates movement, says Emily Hill, MD, a movement disorder physician at UC Health in Cincinnati.

“In Huntington’s disease, those circuits are affected in a way that causes excessive involuntary movement (movements that your body makes that you can’t control), which shows up as chorea,” Dr. Hill says.

Treatment Options for Chorea

Not everyone with chorea needs medication: Treatment decisions are typically based on how much symptoms interfere with daily life and safety, says Hill.

“Is chorea getting in the way of getting dressed? Is it making walking more difficult?” she says. When treatment is needed, there are several types of medications that may help.

FDA-Approved Treatments

The main treatments for chorea block or reduce dopamine.

When dopamine is in the deep parts of the brain, it primarily affects movement — a different function from being a "happiness chemical,” which is what most people are familiar with, says Hill. “Too much movement is often related to too much dopamine,” she adds.

Three medications, known as vesicular monoamine transporter 2 (VMAT2) inhibitors, are approved by the U.S. Food and Drug Administration (FDA) to treat chorea in Huntington’s disease.

  • Deutetrabenazine (Austedo) reduces dopamine signaling and is designed to last longer in the body than tetrabenazine, allowing less frequent dosing.
  • Tetrabenazine (Xenazine) works in a similar way to deutetrabenazine by reducing the release of dopamine into the synapse, which helps calm excessive involuntary movements.
  • Valbenazine (Ingrezza) is a newer VMAT2 inhibitor that also works similarly to control chorea.
Chorea often improves with these treatments, Hill says, though people may still have some involuntary movement even while taking them.

Other Medications That May Help Control Chorea

If first-line VMAT2 inhibitors aren’t effective or aren’t well tolerated, doctors may consider other medications to suppress chorea, including the following:

  • Amantadine (Gocovri ER, Osmolex ER) may help reduce involuntary movements in some people, though results vary.
  • Clonazepam (Klonopin), a benzodiazepine, may help reduce excessive movements and can also ease anxiety that may worsen symptoms.
  • Levetiracetam (Keppra, Elepsia XR, Spritam), an anticonvulsant, is sometimes used off-label to help control involuntary movements.

Antipsychotics With Anti-Chorea Effects

Antipsychotic medications are also used off-label to suppress chorea, though the evidence is limited. They may also be prescribed to help with two things at once in people with agitation. Options include:

  • Olanzapine (Zyprexa)
  • Aripiprazole (Abilify, Aristada)
  • Risperidone
  • Haloperidol, typically reserved for severe or hard-to-treat cases

Side Effects and Limitations of Treatment

Side effects and limitations are an important consideration for any medication, and this is especially true of chorea treatment. It can be a balancing act of reducing involuntary movements without creating new problems that feel just as disruptive.

VMAT2 inhibitors can cause sleepiness, nausea, restlessness, and stiffness or slowed movement. In some people, they can tip the balance too far in the other direction, leading to more rigidity or parkinsonism-like symptoms.

The medications can have mood side effects as well, though sometimes it’s difficult to separate those from symptoms caused by Huntington’s disease itself. Tetrabenazine is the drug most closely linked with depression and suicidal thoughts. An adverse event study also found reports of suicidal ideation and parkinsonism across the VMAT2 class, though it could not prove the drugs caused those problems.

Antipsychotics can also cause a range of side effects, including abnormal movements, sleepiness, stiffness, and restlessness. Older antipsychotics generally have more side effects than newer, atypical options.

Treatment also has limits over time. Anti-chorea therapy should be reevaluated regularly, because as Huntington’s progresses, the focus of care may shift.

“Typically, as symptoms progress, the thinking, memory, and behavior symptoms are the more disabling features,” says Hill.

Also, some medications that help with some symptoms may cause side effects that include worsening other symptoms. People with Huntington’s disease may also develop other movement problems like dystonia (abnormal muscle contractions) or even Parkinson-like symptoms, she says.

Chorea treatment is often a balancing act, and that’s why regular check-ins with a neurologist are so important: The best treatment or treatments early on may not still be the right ones later.

Lifestyle Approaches to Managing Chorea

Lifestyle strategies can play an important role in managing chorea, particularly when symptoms are mild or fluctuate. They include:

  • Reducing Stress and Triggers Chorea can worsen with stress and anxiety, so managing emotional triggers may help reduce symptoms.
  • Creating Structured Routines Caregivers can help by setting schedules that allow extra time for dressing, hygiene, meals, and daily activities.
  • Focusing During Eating Chorea can make chewing and swallowing difficult, which can increase the risk of choking. Removing distractions during meals and selecting foods that are easier to eat can help.

The Takeaway

  • Chorea is common in Huntington’s disease, but it does not always need treatment right away.
  • When chorea starts to affect safety or daily life, VMAT2 inhibitors are the main FDA-approved treatment option.
  • Medication side effects and disease changes mean that the best treatment can change over time. Regular check-ins with a neurologist are essential.
  • Lifestyle changes, like reducing stress, allowing extra time for tasks, and making meals easier can also help.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Huntington’s Disease. Mayo Clinic. April 25, 2024.
  2. Chorea. Cleveland Clinic. December 1, 2023.
  3. Huntington’s Disease: Diagnosis & Treatment. Mayo Clinic. April 25, 2024.
  4. Stimming EF et al. Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington’s Disease: Data from Enroll-HD. Neurology and Therapy. January 15, 2025.
  5. Huntington Disease: Treatment of Manifestations. Gene Reviews. February 12, 2026.
  6. Stimming EF et al. Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington’s Disease: Data from Enroll-HD. Neurology and Therapy. January 15, 2025.
  7. Tan AM et al. Antidopaminergic Medications in Huntington’s Disease. Journal of Huntington’s Disease. January 12, 2025.
  8. Wong S et al. Risk of VMAT2 inhibitors on Suicidality and Parkinsonism: Report Utilizing the United States Food and Drug Administration Adverse Event Reporting System. International Clinical Psychopharmacology. May 2025.
  9. Antipsychotic Medications. Cleveland Clinic. November 11, 2024.
  10. A Physician’s Guide to the Management of Huntington’s Disease. Huntington’s Disease Society of America.
jason-paul-chua-bio

Jason Paul Chua, MD, PhD

Medical Reviewer

Jason Chua, MD, PhD, is an assistant professor in the Department of Neurology and Division of Movement Disorders at Johns Hopkins School of Medicine. He received his training at th...

Becky Upham, MA

Becky Upham

Author

Becky Upham has worked throughout the health and wellness world for over 25 years. She's been a race director, a team recruiter for the Leukemia and Lymphoma Society, a salesperson...